NEVRO CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.33 USD | -0.21% |
|
-2.00% | -56.64% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The stock, which is currently worth 2024 to 0.57 times its sales, is clearly overvalued in comparison with peers.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -56.32% | 343M | C+ | ||
| -6.37% | 178B | C+ | ||
| -0.36% | 107B | C | ||
| -2.23% | 67.04B | A | ||
| -7.64% | 47.23B | B- | ||
| +11.42% | 44.62B | B- | ||
| +9.25% | 42.5B | B+ | ||
| +15.46% | 29.99B | B | ||
| +15.97% | 25.22B | A- | ||
| -7.08% | 24.14B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NVRO Stock
- Ratings Nevro Corp.
